-
-
NEFAZODONE HCL
- QTY 14
- 200 MG
- Tablet
- Near 77381
NEFAZODONE (nef AY zoe done) treats depression. It increases the amount of serotonin and norepinephrine in the brain, substances that help regulate mood.
Change Location
Set Price Drop Alert for:
NEFAZODONE HCL
- QTY 14
- 200 MG
- Tablet
What does Supply mean?
If your selected quantity is intended to last longer than one month, please recheck the price using the 3-months supply option. In some cases, the estimated drug price may vary depending on the supply duration.
More Ways to Save On:
NEFAZODONE HCL
- QTY 14
- 200 MG
- Tablet
You may find alternative ways to save with this medication. Talk to your pharmacist about the potential option(s) noted below.
Medicine Chest
NEFAZODONE HCL Lifestyle Interactions
-
Nefazodone Hydrochloride 200mg, Oral tablet
• Interaction: Alcohol• Severity: Major• Notes for Consumers: Do not drink alcohol while taking this medication. Drinking alcohol while taking this medication can cause serious side effects, such as central nervous system (CNS) depression, and can increase the risk of falling. Call emergency services right away if you experience symptoms of CNS depression: slow or shallow breathing, shortness of breath, feeling faint, dizziness, confusion, trouble staying awake.• Notes for Professionals: Advise patients to avoid alcohol consumption while taking CNS depressants. Alcohol consumption may result in additive CNS depression. -
Nefazodone Hydrochloride 200mg, Oral tablet
• Interaction: Cannabis• Severity: Major• Notes for Consumers: Discuss cannabis use with your care team. The effects of cannabis may be altered if used with your medication. Call emergency services right away if you experience slow or shallow breathing, shortness of breath, feeling faint, dizziness, confusion, or trouble staying awake.• Notes for Professionals: Advise patients to avoid cannabis use during nefazodone treatment. Concomitant use may alter the exposure of some cannabinoids and increase the risk for adverse reactions. The cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are CYP3A substrates and nefazodone is a strong CYP3A inhibitor. Concomitant use of a cannabinoid product containing THC and CBD at an approximate 1:1 ratio with another strong CYP3A inhibitor increased THC, 11-OH-THC, and CBD peak exposures by 1.3-, 3-, and 1.9-fold respectively.
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.
